Anthropic

Explore the latest insights on Anthropic and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Anthropic’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Alphamab Oncology Doses First Patient in Phase III Trial of JSKN033 – World's First High‑Concentration Subcutaneous HER2 ADC/PD‑L1 Fixed‑Dose Combination for Recurrent Cervical Cancer
CompanyDrug

Alphamab Oncology Doses First Patient in Phase III Trial of JSKN033 – World’s First High‑Concentration Subcutaneous HER2 ADC/PD‑L1 Fixed‑Dose Combination for Recurrent Cervical Cancer

Alphamab Oncology (HKG: 9966) announced that the first patient has been successfully dosed in the Phase III clinical study of JSKN033 monotherapy for recurrent or metastatic cervical cancer – irrespective…

Junshi Biosciences Converts Loqtorzi Urothelial Carcinoma Indication to Full Approval; Subcutaneous Toripalimab (JS001sc) NDA Accepted in First‑Line HER2‑Expressing Disease

Junshi Biosciences Converts Loqtorzi Urothelial Carcinoma Indication to Full Approval; Subcutaneous Toripalimab (JS001sc) NDA Accepted in First‑Line HER2‑Expressing Disease

Eli Lilly's Retatrutide Beats Ozempic Head‑to‑Head in Phase 3 TRANSCEND-T2D-2 – Greater A1C Reduction and Roughly Double the Weight Loss in Type 2 Diabetes

Eli Lilly’s Retatrutide Beats Ozempic Head‑to‑Head in Phase 3 TRANSCEND-T2D-2 – Greater A1C Reduction and Roughly Double the Weight Loss in Type 2 Diabetes

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Novo Nordisk and Anthropic Announce AI Collaboration – Claude Science to Accelerate Drug Discovery and AI‑Driven Software Development
CompanyDeals

Novo Nordisk and Anthropic Announce AI Collaboration – Claude Science to Accelerate Drug Discovery and AI‑Driven Software Development